Claudin 18.2 靶向：泛癌视角
Claudin 18.2 Targeting: A Pan-Cancer Perspective.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向胃肠道肿瘤中的 CLDN18.2：新药与新适应证
英文原题：Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications.
查看英文原题
Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胃肠道（GI）癌症对全球癌症负担和癌症相关死亡贡献巨大。Claudin-18.2（CLDN18.2）是一种跨膜蛋白，是紧密连接的主要组成成分，在维持屏障功能中发挥重要作用。CLDN18.2在肿瘤组织中广泛表达，且胞外环暴露，这些特征使其成为研究者开发胃肠道癌症靶向策略和免疫疗法的理想靶点。本综述重点讨论CLDN18.2表达模式及其在胃肠道癌症中的临床意义。我们还讨论CLDN18.2促进和/或抑制肿瘤的作用、调控其表达的机制，以及目前临床研究中靶向CLDN18.2药物的开发进展。
展开英文摘要原文
Cancers of the gastrointestinal (GI) tract greatly contribute to the global cancer burden and cancer-related death. Claudin-18. 2(CLDN18. 2), a transmembrane protein, is a major component of tight junctions and plays an important role in the maintenance of barrier function.
Its characteristic widespread expression in tumour tissues and its exposed extracellular loops make it an ideal target for researchers to develop targeted strategies and immunotherapies for cancers of the GI tract. In the present review, we focus on the expression pattern of CLDN18. 2 and its clinical significance in GI cancer.
We also discuss the tumour-promoting and/or tumour-inhibiting functions of CLDN18. 2, the mechanisms regulating its expression, and the current progress regarding the development of drugs targeting CLDN18. 2 in clinical research.
论文信息
- 作者
- Chen J、Xu Z、Hu C、Zhang S、Zi M、Yuan L、Cheng X
- 单位
- Department of Gastric Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institutes of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2023
- 原文标识
- PubMed 36969060 · DOI 10.3389/fonc.2023.1132319
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →